Complete Onco Analysis (Multi-Marker Panel)

What It Measures

• Tumour markers: CEA, CA 19-9, CA-125, AFP, PSA/free PSA, CA 15-3, HCG, NSE, S100B (cancer-specific selection)
• Immune panel: Total lymphocytes, NK cell count and activity, CD4/CD8 ratio, T-reg cells
• Inflammatory status: hsCRP, ESR, IL-6, ferritin, fibrinogen
• Metabolic panel: fasting glucose, insulin, HbA1c, IGF-1 (cancer fuel environment)
• Nutritional oncology markers: Vitamin D3 (25-OH), Vitamin B12, folate, zinc, selenium, magnesium
• Oxidative stress: 8-OHdG (DNA oxidation), lipid peroxidation markers
• Liver and kidney function (treatment tolerance assessment)
• Coagulation: D-dimer, fibrinogen (cancer-associated thrombosis risk)

How It Works

A fasting blood draw (typically 20–30 ml across multiple tubes) is collected. Samples are processed in separate assays across multiple laboratory departments — clinical biochemistry for metabolic and tumour markers, immunology for immune phenotyping, specialist labs for inflammatory cytokines. Results are compiled into a single report. Interpretation requires an integrative oncologist or physician who can contextualise the combined findings against the patient's clinical picture, cancer type, and treatment history.

• Patients wanting a holistic baseline before starting any protocol (conventional or integrative)
• Those in active treatment wanting to monitor immune function, inflammation, and nutritional status
• Post-treatment surveillance — tracking tumour markers and immune recovery
• Patients with unexplained symptoms where a broad screen is needed
• Anyone building an integrative oncology protocol who wants data to personalise supplements and interventions

Individual components of a comprehensive panel have strong evidence. Tumour markers (CEA, CA-125, PSA) are well-validated for monitoring known cancers, though poor as standalone screening tools. NK cell activity as a cancer prognosis marker has moderate evidence — low NK activity predicts worse outcomes in multiple cancer types. Vitamin D deficiency is associated with poorer cancer outcomes across 10+ cancer types in meta-analyses. High fasting insulin and IGF-1 correlate with increased cancer recurrence risk. The combination of all these markers into a single 'complete onco panel' as a decision tool has not been formally validated in RCTs, but is widely used in integrative oncology practice to personalise protocols.

This list is not exhaustive. Ask your oncologist or integrative physician for locally available options.

• Tumour markers are not reliable screening tools in isolation — elevated CEA can come from smoking, IBD, or other non-cancer causes
• Over-testing can lead to anxiety and unnecessary follow-up investigations
• Results require expert interpretation — do not self-interpret
• Panels vary significantly between labs — compare what is included before choosing
• Nutritional supplementation should be guided by results with professional oversight, especially during chemotherapy